---
title: An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry
nct_id: NCT02677961
overall_status: RECRUITING
sponsor: Ohio State University Comprehensive Cancer Center
study_type: OBSERVATIONAL
primary_condition: Neoplasms, Connective and Soft Tissue
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02677961.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02677961"
ct_last_update_post_date: 2026-02-11
last_seen_at: "2026-05-12T07:03:05.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry

**NCT ID:** [NCT02677961](https://clinicaltrials.gov/study/NCT02677961)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 1500
- **Lead Sponsor:** Ohio State University Comprehensive Cancer Center
- **Conditions:** Neoplasms, Connective and Soft Tissue, Bone Neoplasms
- **Start Date:** 2015-07-01
- **Completion Date:** 2027-12-31
- **CT.gov Last Update:** 2026-02-11

## Brief Summary

Translational studies in cancer research can be impeded by the lack of high-quality clinical data that can be correlated with research questions. This is particularly true in the case of rare diseases, such as bone and soft tissue tumors. It is therefore the purpose of this study to create a prospective EHR-based clinical registry for individuals with bone and soft-tissue tumors.

## Detailed Description

PRIMARY OBJECTIVES:

I. To create a secure EHR-based registry to allow for the prospective collection of clinical and research data in a collection of rare diseases (bone and soft-tissue tumors).

II. To facilitate the identification and validation of clinical and molecular features that may be associated with prognosis and/or response to therapy in (subtypes) of bone and soft-tissue tumors.

III. To pilot a mechanism that will facilitate future collaboration between institutions for research and analysis of bone and soft-tissue tumors.

IV. To standardize biospecimen collection for correlative biomarker analysis for patients undergoing treatment and surveillance for bone and soft tissue tumors at Ohio State University.

OUTLINE: This is an observational study.

Patients complete quality of life questionnaires and their medical records are reviewed. Patients may also undergo collection of blood samples for up to 2 years, unless otherwise specified in the protocol.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Must have a diagnosis or presumed diagnosis of bone or soft tissue tumor as defined by the WHO classification of tumors of soft tissue and bone (4th ed.)
* Patient, or his/her designated power of attorney, must be able to understand and approve of the consent to participate.

Exclusion Criteria:

* Prisoners are excluded from participation in the Registry.
```

## Interventions

- **Observation** (OTHER)

## Primary Outcomes

- **Overall Survival** _(time frame: 5 Years)_

## Locations (1)

- Ohio State University, Columbus, Ohio, United States — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.ohio state university|columbus|ohio|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02677961.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02677961*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*